AP 120
Alternative Names: AP120Latest Information Update: 01 Jan 2021
At a glance
- Originator AP Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dendritic cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 30 Nov 2020 AP 120 is available for licensing as of 30 Nov 2020. http://www.apbioinc.com/en/about
- 30 Nov 2020 Early research in Solid tumours in Taiwan (Parenteral) (AP Biosciences pipeline, November 2020)